DFTX.US Definium Therapeutics, Inc.

Healthcare Pharmaceuticals USA Stocks
32.08 USD
Close of Nov 14, 2026
10.47 49.70
Market cap
USD 4.39B
P/E
-
P/B
4.67x
ROE
-39.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DFTX.US undervalued?

Graham number

The Graham number of Definium Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Definium Therapeutics, Inc. fundamental analysis

No fundamental analysis for Definium Therapeutics, Inc. yet.

Definium Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was form…

Full company profile